What is the difference between GHRP-2 and GHRP-6?

GHRP-2: GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnos... GHRP-6: GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) growth hormone secretagogue and ghrelin receptor agonist. Developed by Bowers and Momany and first described in 1984, it was the fir...

GHRP-2 vs GHRP-6

Q: Can you stack GHRP-2 and GHRP-6?

GHRP-2 (performance) and GHRP-6 (performance) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of GHRP-2 and GHRP-6 — mechanism, dosing, side effects, legal status, and pricing.

GHRP-2

GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnostic agent for GH deficiency, but is NOT FDA-approved in the US and is research-only. Unlike ipamorelin, GHRP-2 is non-selective and modestly raises ACTH, cortisol, and prolactin.

Profile Prices Calculator

GHRP-6

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) growth hormone secretagogue and ghrelin receptor agonist. Developed by Bowers and Momany and first described in 1984, it was the first synthetic GHRP characterized and is defined by its pronounced appetite-stimulating effect — the strongest of any clinically studied GHRP. It has never been approved by the FDA or any regulatory agency and remains a research-only compound used off-label in the grey market.

Profile Prices Calculator

GHRP-2

GHRP-6

Category

Performance

Legal Status

Category 1 — Legally Compoundable

Mechanism

GHRP-2 binds the ghrelin/GHS-R1a receptor on pituitary somatotrophs and in the hypothalamus, triggering Gq-coupled calcium signaling and pulsatile GH release while also suppressing somatostatin tone. At therapeutic and supratherapeutic doses it produces measurable rises in ACTH, cortisol, and prolactin (less than GHRP-6 or hexarelin, but more than ipamorelin) and stimulates appetite through ghrelin-pathway activation.

GHRP-6 binds the growth hormone secretagogue receptor 1a (GHSR-1a) on pituitary somatotrophs and hypothalamic neurons, mimicking endogenous ghrelin. Receptor activation (Gq/PLC/IP3) drives intracellular calcium release and pulsatile GH secretion while suppressing somatostatin tone. GHSR-1a activation in the arcuate nucleus strongly stimulates appetite — the hallmark feature of GHRP-6 and its defining difference from the selective GHRP ipamorelin. Compared with GHRP-2, GHRP-6 is generally less potent for raw GH output but more potent for appetite, and both produce modest transient elevations in ACTH, cortisol, and prolactin.

Dose Range

100–300 mcg (grey-market); 100 mcg IV single dose (Japan diagnostic)

100–300 mcg

Route

SubQ or IV

SubQ

Frequency

1–3 times daily (grey-market)

1–3 times daily

Dosing Notes

Research-use only in the US. Grey-market protocols use SubQ on an empty stomach, often stacked with a GHRH analog (CJC-1295/sermorelin) for synergistic GH release. No clinically validated chronic-use dose for anti-aging or body composition.

Research-only; no approved human indication. Grey-market protocols use 100–300 mcg SubQ 1–3x/day, typically on an empty stomach. A strong hunger response is expected within 15–20 minutes and is the defining feature versus ipamorelin. Often stacked with a GHRH analog (CJC-1295, sermorelin) for synergistic GH pulses. Less commonly used than GHRP-2 or ipamorelin due to the intense appetite stimulation.

Side Effects

Increased appetite (ghrelin effect)
Water retention
Facial flushing
Transient ACTH, cortisol, and prolactin elevation
Tingling/numbness in extremities
Injection-site reactions
Insulin resistance / hyperglycemia risk with sustained GH elevation

Intense hunger within 15–20 minutes (hallmark feature)
Water retention and bloating
Facial flushing
Lethargy or drowsiness
Transient rise in ACTH, cortisol, and prolactin
Tingling or numbness in extremities
Injection-site reactions
Insulin resistance with chronic use (theoretical)

Contraindications

Active malignancy (theoretical IGF-1–driven risk)
Pregnancy or breastfeeding
Uncontrolled diabetes or insulin resistance
Not FDA-approved — research use only in the US

Active malignancy (theoretical IGF-1-mediated risk)
Uncontrolled diabetes or insulin resistance
Pregnancy or breastfeeding
Obesity or weight-loss goals (intense appetite stimulation)
Not FDA-approved — research use only

GHRP-2 Research Summary

Pralmorelin is approved in Japan as a diagnostic GH-stimulation test (100 mcg IV; peak GH <15 mcg/L cut-off validated against the insulin tolerance test by Chihara et al., 2007). Arvat et al. (1997) showed GHRP-2 raises GH, prolactin, ACTH, and cortisol in healthy men (comparable to hexarelin). Laferrère et al. (2005) demonstrated GHRP-2 infusion increases food intake in healthy men. There are no FDA-approved indications; anti-aging and performance use is unvalidated grey-market use.

Key references

GHRP-6 Research Summary

Bowers, Momany, Reynolds, and Hong first described GHRP-6 in Endocrinology (1984), making it the prototype synthetic GH secretagogue and a key tool in the later discovery of the ghrelin receptor. Ghigo et al. (1997) reviewed the GHRP class and confirmed GH, ACTH/cortisol, and prolactin co-stimulation patterns in humans. Berlanga et al. (Clinical Science, 2007; and a 2017 historical review) demonstrated cytoprotective and cardioprotective effects in myocardial infarction and ischemia-reperfusion models, attributed to antioxidant and CD36-mediated mechanisms independent of GH release. GHRP-6 has never been approved for any clinical indication.

Key references

Can you stack GHRP-2 and GHRP-6?

GHRP-2 and GHRP-6 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

BPC-157 vs TB-500 Semaglutide vs Tirzepatide Ipamorelin vs CJC-1295 CJC-1295 vs Sermorelin Semaglutide vs Liraglutide Selank vs Semax BPC-157 vs GHK-Cu MK-677 vs Ipamorelin

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.

GHRP-2

GHRP-6

GHRP-2 Research Summary

GHRP-6 Research Summary

Can you stack GHRP-2 and GHRP-6?